Arca
Skip to content
Tools
Tools

Pancreatic cancer

Drug research and approvals for pancreatic cancer: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 21, 2026, 886 studies of pancreatic cancer are recruiting on ClinicalTrials.gov, Health Canada has authorized 24 drug trials for it since 2013, and FDA has 6 approved and 226 open orphan designations naming it.

  • Recruiting worldwide: 886
  • Trials authorized in Canada: 24
  • FDA orphan approvals: 6
  • EU medicines: 0

Recruiting now

Newest posted first, of 886 recruiting on ClinicalTrials.gov ↗

Drug pipeline

Each drug at the furthest stage it has reached for this condition or a subtype of it, from ChEMBL's drug indications

Approved 8

  • GemcitabineRibonucleoside-diphosphate reductase RR1 inhibitor
  • PaclitaxelTubulin inhibitor
  • IrinotecanDNA topoisomerase I inhibitor
  • ErlotinibEpidermal growth factor receptor erbB1 inhibitor
  • OlaparibPARP 1, 2 and 3 inhibitor
  • EverolimusFK506-binding protein 1A inhibitor
  • DiazoxideIslet cell adenoma · Potassium channel, inwardly rectifying, subfamily J, member 11 opener
  • ZenocutuzumabErbB-2/ErbB-3 heterodimer inhibitor

Phase 3 12 of 56

Phase 2 12 of 218

Phase 1 or earlier 12 of 153

How its trials ended

2,776 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrong

Of the 638 whose ending is known, 21% met their primary endpoint, 12% missed it and 67% stopped early.

  • Completed, result not reported90833%
  • Ongoing82530%
  • Status unknown40515%
  • Stopped: other or unclear2077%
  • Met its primary endpoint1335%
  • Stopped: enrollment or feasibility1044%
  • Missed its primary endpoint773%
  • Stopped: sponsor or business decision522%
  • Stopped: lack of efficacy351%
  • Stopped: funding211%
  • Stopped: safety9<1%

Trials authorized in Canada

The 10 newest of 24; search them all in Canada trials
Oct 29, 2026A phase 2, open-label, master protocol study to evaluate safety and efficacy of treatment combinations with telisotuzumab adizutecan in subjects with…Telisotuzumab adizutecan (ABBV-400) / GemcitabineAbbViePending
Aug 14, 2024Phase I open-label, multi-center study to evaluate the safety, tolerability, dosimetry, and preliminary activity of [177lu]LU-NNS309 in patients with…[177LU]LU-NNS309 (FXX489) / [68GA]GA-NNS309 (FFG233)Novartis PharmaceuticalsOngoing
Jul 15, 2024Microbubble-assisted MRI-guided focused ultrasound with chemotherapy in locally advanced unresectable pancreatic cancer (focus-lapc)OxaliplatinArrayus Technologies Inc.Pending
Mar 26, 2024A phase 1b study evaluating the safety, tolerability, pharmacokinetics, and efficacy of amg 193 in combination with other therapies in subjects with advanced…Amg 193AmgenPending
May 31, 2023A phase 1 study of olaparib in combination with durvalumab (MEDI4736) and concurrent radiation therapy following first-line chemotherapy in locally advanced…Olaparib / DurvalumabUniversity Health NetworkOngoing
Aug 19, 2021Greco-2: a randomized, phase 2 study of stereotactic body radiation therapy (SBRT) in combination with GC4711 in the treatment of unresectable or borderline…Avasopasem (GC4711)Galera TherapeuticsOngoing
Jun 3, 2020A phase 2 study of saltikva (attenuated salmonella typhimurium containing the human gene for interleukin-2) in patients with unresectable pancreatic cancerSaltikva (attenuated salmonella typhimurium containing the human gene for…Salspera LlpOngoing
Mar 23, 2020Feasibility study of hypoxia and re-oxygenation imaging in pancreatic cancer using positron emission tomography (PET) with [18f] fluoroazomycin-arabinoside…[F-18]-FAZAPrincess Margaret Cancer CentreOngoing
Feb 28, 2020A phase II/III randomized, open-label clinical study of napabucasin in combination with weekly paclitaxel and low-dose gemcitabine in patients with metastatic…Napabucasin (GB201) / Paclitaxel1Globe Health InstituteOngoing
Jan 13, 2020"a phase 3, randomized, double-blindstudy of pamrevlumabor placeboin combination with gemcitabine plus nab-paclitaxelas neoadjuvant treatment in patients with…Pamrevlumab (FG-3019)Fibrogen IncorporatedOngoing

FDA orphan designations

Approved first, then open designations, newest first; 15 of 232
Aug 26, 2026RasonqueTreatment of adult patients with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or who are not…Revolution Medicines, Inc.Approved
Dec 4, 2024BizengriTreatment of adults with advanced unresectable or metastatic pancreatic adenocarcinoma harboring a neuregulin 1 (NRG1) gene fusion with…Partner Therapeutics, Inc.Approved
Feb 13, 2024OnivydeIn combination with oxaliplatin, fluorouracil and leucovorin for the first-line treatment of adult patients with metastatic pancreatic…Ipsen Biopharmaceuticals, Inc.Approved
Dec 27, 2019LynparzaLynparza is indicated for the maintenance treatment of adult patients with deleterious or suspected deleterious gBRCAm metastatic…AstraZeneca Pharmaceuticals LPApproved
Oct 22, 2015Irinotecan liposome injectionFor use in combination with fluorouracil and leucovorin, for the treatment of patients with metastatic adenocarcinoma of the pancreas that…Ipsen Biopharmaceuticals, Inc.Approved
Sep 6, 2013AbraxaneTreatment of metastatic adenocarcinoma of the pancreas as first-line treatment, in combination with gemcitabine.Abraxis BioScience, LLCApproved
Oct 5, 2026225Ac chelated with SKL35500 (consists of a ligand, a…Treatment of pancreatic cancerSK Life Science, Inc.Designated
Oct 5, 2026OlomorasibTreatment of pancreatic cancerEli Lilly and CompanyDesignated
Sep 21, 2026Nuzefatide pevedotinTreatment of pancreatic cancerBicycleTx LtdDesignated
Sep 15, 2026ZoldonrasibTreatment of pancreatic cancerRevolution Medicines, Inc.Designated
Sep 14, 2026Antibody drug conjugate composed of recombinant humanized…Treatment of pancreatic cancerArriVent BioPharma Inc.Designated
Sep 11, 2026Anti-CDH17 monoclonal antibody-DNA topoisomerase I…Treatment of pancreatic cancerWealth Venture US IncDesignated
Aug 27, 2026Flavopereirine-derived beta-carboline alkaloid DNA…Treatment of pancreatic cancerMirkine Pharma, IncorporatedDesignated
Jul 21, 2026Anti-tissue factor monoclonal antibody conjugated to…Treatment of pancreatic cancerJiangsu Hengrui Pharmaceuticals Co., Ltd.Designated
Jul 9, 2026MTA-cooperative PRMT5 inhibitorTreatment of pancreatic cancerBeOne Medicines USA, Inc.Designated

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.